Filing Flows › Lyell Immunopharma (LYEL) › Q3 2026
Lyell Immunopharma (LYEL) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Lyell Immunopharma (LYEL) reported revenue of $3K for the third quarter 2026 (Q3 2026), -80% from a year earlier and -25% from the quarter before.
Lyell Immunopharma, Q3 2026: revenue $3K (-80% year over year), net loss $45.5M, operating cash flow −$34.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3K | -25% | -80% |
| Operating profit | −$48.3M | — | — |
| Net earnings | −$45.5M | — | — |
| Operating cash flow | −$34.6M | — | — |
What changed
Revenue was $3K in Q3 2026, down 80% year over year and down 25% from the previous quarter.
Operating costs exceeded revenue by $48.3M, an operating margin of -1609833.3%. Total costs grew 30% against a revenue fall of 80%. The quarter ended with a net loss of $45.5M, wider than the previous quarter's $44.8M loss.
Operating cash flow was −$34.6M. Non-cash charges added back $2.1M of depreciation and amortization and $4.5M of share-based compensation. Working capital and other items added $4.4M. Capital expenditures of $66K exceeded it, leaving free cash flow of −$34.6M.
Questions
What was Lyell Immunopharma's revenue in the third quarter 2026?
Lyell Immunopharma (LYEL) reported revenue of $3K for the third quarter 2026 (Q3 2026), -80% from a year earlier and -25% from the quarter before.
Source: Lyell Immunopharma 10-Q on SEC EDGAR.